G. Brink

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Wim H van Harten, Valesca P Retel, Guido Brink, 2007, The Lancet. Oncology.

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2

E. Mariman, L. J. Veer, H. Brunner, 1999, British Journal of Cancer.

A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.

G. Pals, P. Devilee, A. V. D. van den Ouweland, 1997, American journal of human genetics.

Cost-effectiveness of targeting chemotherapy with the 70-gene prognostic signature in early-stage breast cancer (ESBC) patients.

G. Brink, R. Bender, E. Chen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial

Laurent Jacob, Anke Witteveen, Inès Beumer, 2020, Communications Biology.

Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial

T. Speed, A. Witteveen, A. Glas, 2020, Communications Biology.

Equivalence of MammaPrint array types in clinical trials and diagnostics

A. Witteveen, A. Glas, L. Delahaye, 2016, Breast Cancer Research and Treatment.

5167 French cost effectiveness study of the MammaPrint 70-gene signature in early stage breast cancer patients

G. Brink, F. Snoo, L. Boubli, 2009 .

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

M. J. van de Vijver, J. Peterse, D. Atsma, 2007, The Lancet. Oncology.